Source: Business Standard

Aurobindo Pharma: Aurobindo Pharma rallies after receiving USFDA nod for Rivaroxaban tablets

Aurobindo Pharma jumped 3.42% to Rs 1,119.55 after the pharma company said that it has received final approval from US Food and Drug Administration (USFDA) to manufacture and market Rivaroxaban Tablets USP, 2.5 mg.

Read full article »
Aurobindo Pharma's Competitors | Aurobindo Pharma's News | Aurobindo Pharma's Financials
Stay up-to-date with the latest news on Aurobindo Pharma
Est. Annual Revenue
$1.0-5.0B
Est. Employees
10-50K
K.Nithyananda Reddy's photo - Managing Director of Aurobindo Pharma

Managing Director

K.Nithyananda Reddy

CEO Approval Rating

75/100

Read more
Stay up-to-date with the latest news on Aurobindo Pharma